Maria Pia Sormani

Apr 12, 2024 | nature.com | Michael Khalil |Sylvain Lehmann |Markus Otto |Fredrik Piehl |Stefan Bittner |Maria Pia Sormani | +8 more

AbstractNeurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and simplify longitudinal follow-up has paved the way for the development of neurofilaments as a biomarker in clinical practice.

Aug 21, 2023 | jamanetwork.com | Christine Lebrun-Frenay |Université Cote d’Azur |Aksel Siva |Maria Pia Sormani

Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial Key PointsQuestion  Is it possible to prevent multiple sclerosis with a disease-modifying treatment in people with preclinical demyelinating disease?

Aug 9, 2023 | journals.sagepub.com | Maria Pia Sormani |Jeremy Chataway |Ruth Ann Marrie

IntroductionOutcomes in multiple sclerosis (MS) are well recognized to be heterogeneous. This heterogeneity may also extend to therapeutic responses and adverse effects and can be accounted for by multiple factors including genetic differences, as well as age, sex, liver or renal function, health behaviors, and disease severity.1 For example, genetic variation influences the expression of thiopurine S-methyltransferase (TPMT) enzyme.